Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Mayo Clinic |
---|---|
Information provided by: | Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT00493792 |
A prospective, randomized, blinded clinical trial is proposed to compare Stryker Orthopaedics N2Vac Polyethylene to their X3 Polyethylene when used with the Triathlon Posterior Stabilized (PS) total knee system.
Condition | Intervention | Phase |
---|---|---|
Arthroplasty, Replacement, Knee Total Knee Replacement |
Device: Stryker X3 crosslink |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Subject), Historical Control, Parallel Assignment, Efficacy Study |
Official Title: | A Prospective, Randomized Study Comparing the Survival for X-3 Polyethylene to N2Vac Polyethylene When Used With the Triathlon Posterior Stabilized (PS) Total Knee System. |
Estimated Enrollment: | 572 |
Study Start Date: | February 2007 |
Estimated Study Completion Date: | December 2021 |
Estimated Primary Completion Date: | December 2020 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
|
Device: Stryker X3 crosslink
Radiographs, questionnaires and an exam will be obtained at key post-surgical follow up dates. 3months, 2years, 5 years, 7 years and 10 years.
|
2
X3 Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
|
Device: Stryker X3 crosslink
Radiographs, questionnaires and an exam will be obtained at key post-surgical follow up dates. 3months, 2years, 5 years, 7 years and 10 years.
|
This is a fixed-bearing knee intended for use in patients undergoing cemented total knee arthroplasty. The devices to be used are both FDA approved via 510k clearance.
A total of 572 cases (286 per group) will be entered. Each patient will be assessed pre-operatively and post-operatively at three months and two, five, seven and ten years. The primary endpoint will be the revision rate at ten years. The result for these will be analyzed using an unconditional test of equivalence between two independent binomials. Chi-square analysis will be used to compare the instance of mortality, revision surgery, deep vein thrombosis, pulmonary embolus, neurovascular complication, and infection. Other outcome measures incorporated in the Knee Society Clinical rating scale will undergo appropriate generalized linear regression for the type of outcome involved. The primary aim of the study is to compare the survivorship of two types of polyethylene (conventional N2Vac and highly cross-linked X3) used in a fixed-bearing total knee system in patients undergoing cemented total knee arthroplasty. These results will be measured through radiographs at each post-operative interval with an independent radiograph review being performed after all patients have reached 7 and 10 year follow-up. Secondary results will also be collected and will focus on disease-specific (Knee Society Scores), global (SF-12), and outcome measures. Radiographic results consisting of standing anteroposterior, lateral and Merchant views of the surgical knee will be recorded and analyzed. Completion of the initial investigation will occur at the 10-year interval after the last enrolled.
Ages Eligible for Study: | 21 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
United States, Arizona | |
Mayo Clinic | Recruiting |
Scottsdale, Arizona, United States, 85259 | |
Contact: Christine Moffat 480-342-8000 moffat.christine@mayo.edu | |
Principal Investigator: Henry D. Clarke, M.D. | |
United States, Florida | |
Mayo Clinic | Recruiting |
Jacksonville, Florida, United States, 32224 | |
Contact: Vickie S. Baker 904-953-2000 baker.vickie@mayo.edu | |
Principal Investigator: Cedric J. Ortiguera, M.D. | |
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Angela S. Barraza, A.S. 507-538-3562 barraza.angela@mayo.edu | |
Principal Investigator: Michael J. Stuart, M.D. |
Principal Investigator: | Michael J. Stuart, M.D. | Mayo Clinic |
Responsible Party: | Mayo Clinic Rochester ( Michael J. Stuart, M.D. ) |
Study ID Numbers: | 06-003093, 06-003093 |
Study First Received: | June 26, 2007 |
Last Updated: | May 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00493792 |
Health Authority: | United States: Institutional Review Board |